Chimerix Aiming to ‘SUPPRESS’ CMV Infection in Phase III
By Jennifer Boggs
Monday, September 9, 2013
Only a few months after its impressive Nasdaq debut, antiviral firm Chimerix Inc. started dosing in its Phase III SUPPRESS trial testing oral nucleotide analogue lipid-conjugate brincidofovir (CMX001) for the prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant recipients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.